Drug class · Endocrine & metabolism
Insulins and insulin analogs
Human insulin and modified insulin molecules (analogs), supplied in vials, cartridges and prefilled pens.
FDA-listed products
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Toujeoinsulin glargine | Insulin glargine 300 U/mL | Injection, SolutionSubcutaneous | Sanofi-Aventis U.S. LLC | 0024-5869 |
| Toujeoinsulin glargine | Insulin glargine 300 U/mL | Injection, SolutionSubcutaneous | A-S Medication Solutions | 50090-2193 |
| TOUJEO Maxinsulin glargine | Insulin glargine 300 U/mL | Injection, SolutionSubcutaneous | Sanofi-Aventis U.S. LLC | 0024-5871 |
| TOUJEO Maxinsulin glargine | Insulin glargine 300 U/mL | Injection, SolutionSubcutaneous | A-S Medication Solutions | 50090-4177 |
| Tresibainsulin degludec | Insulin degludec 200 U/mL | Injection, SolutionSubcutaneous | A-S Medication Solutions | 50090-7094 |
| Tresibainsulin degludec | Insulin degludec 200 U/mL | Injection, SolutionSubcutaneous | A-S Medication Solutions | 50090-3491 |
| Tresibainsulin degludec | Insulin degludec 200 U/mL | Injection, SolutionSubcutaneous | Novo Nordisk | 0169-2550 |
| Tresibainsulin degludec | Insulin degludec 100 U/mL | Injection, SolutionSubcutaneous | Novo Nordisk | 0169-2660 |
| Tresibainsulin degludec | Insulin degludec 100 U/mL | Injection, SolutionSubcutaneous | Novo Nordisk | 0169-2662 |
| Xultophy 100/3.6insulin degludec and liraglutide | Insulin degludec 100 [iU]/mL; Liraglutide 3.6 mg/mL | Injection, SolutionSubcutaneous | Novo Nordisk | 0169-2911 |